24/7 Market News Snapshot 27 August, 2025 – Mannkind Corporation (NASDAQ:MNKD)

August 27, 2025

DENVER, Colo., 27 August, 2025 (www.247marketnews.com) – (NASDAQ:MNKD) are discussed in this article.
MannKind Corporation is experiencing a noteworthy surge in market activity, opening at $4.20 and currently trading at $4.545, an increase of approximately 11.67%. This upward movement follows a previous close at $4.070, supported by an impressive trading volume of 6.75 million shares, indicating heightened investor interest and potential for a breakout. Technical indicators reveal that MannKind is nearing critical resistance levels, warranting close monitoring by traders, as these levels may present opportunities for profit-taking or further strategic positioning. Overall, the current trend reflects a bullish sentiment in the market toward MannKind.

In addition to market activity, MannKind is excited to announce the expansion of its collaboration with United Therapeutics Corporation. United Therapeutics recently opted to develop a second dry powder inhalation therapy under the pre-existing agreement, building on the successful launch of Tyvaso DPI, which received FDA approval in May 2022. The new agreement allows MannKind to utilize its proprietary Technosphere® platform to formulate an investigational molecule, while United Therapeutics will lead the preclinical and clinical development of this promising therapy aimed at treating pulmonary hypertension.

Michael Castagna, PharmD, CEO of MannKind Corporation, expressed enthusiasm about the deepening partnership, emphasizing the company’s commitment to bringing innovative inhaled therapies to patients with pulmonary hypertension. This collaboration underscores both the strength of the partnership and the adaptability of MannKind’s dry powder formulations and inhalation devices.

MannKind will receive an upfront payment of $5 million as part of the expanded agreement, along with opportunities for additional development milestone payments totaling up to $35 million and 10% royalties on net sales of any resulting product. The formulation and development activities for the new investigational molecule are slated to commence immediately, reinforcing MannKind’s dedication to addressing significant unmet medical needs in pulmonary diseases and endocrine conditions.

Related news for (MNKD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.